Dyne Therapeutics, Inc (DYN) Stock AnalysisDYNDyne Therapeutics, Inc

Dyne Therapeutics, Inc. is a clinical-stage neuromuscular disease company. It is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). It has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Dyne Therapeutics is not a good buy right now due to its current price of $14.25, which is significantly below the analyst price targets of $30 and $32. The RSI is at 24.074, indicating the stock is oversold, but the negative sentiment from recent trial failures and a 5-day change of -14.36% raises concerns about its short-term viability. The main risk is the company's ongoing losses, with a net income of -178,556,000 USD in Q2 2026, which could further depress stock prices.

8 analysts cover DYN: 4 rate it Buy, 4 Hold and 0 Sell. The average price target is 39.33.